What one share of Relmada Therapeutics holds
Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology company. We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025.
Relmada Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.85 |
|---|---|
| Cash and investments | $0.11 |
| Book value | $1.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$63.33 | — | — | — | −$34.26 |
| 2013 | — | −$163.60 | $0.07 | −$18.49 | — | — |
| 2015 | — | −$8.37 | $0.01 | −$6.54 | — | $3.27 |
| 2016 | — | −$1.03 | $0.19 | −$4.73 | — | $2.34 |
| 2017 | — | −$2.08 | $0.02 | −$2.16 | — | $0.47 |
| 2018 | — | −$2.86 | $0.00 | −$1.92 | — | −$1.76 |
| 2019 | — | −$2.74 | — | — | — | $0.78 |
| 2019 | — | −$1.62 | $9.18 | −$10.49 | — | $8.00 |
| 2020 | — | −$3.81 | $11.67 | −$13.46 | — | $6.46 |
| 2021 | — | −$7.16 | — | — | — | $7.51 |
| 2022 | — | −$5.30 | — | — | — | $4.67 |
| 2023 | — | −$3.28 | — | — | — | $2.84 |
| 2024 | — | −$2.65 | — | — | — | $1.18 |
| 2025 | — | −$1.45 | — | — | — | $1.18 |
Common questions about Relmada Therapeutics
How much does one share of Relmada Therapeutics earn?
Over the last 12 months, Relmada Therapeutics lost $0.85 for each share.
Does Relmada Therapeutics pay a dividend?
Relmada Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Relmada Therapeutics’s book value per share?
Relmada Therapeutics’s book value is $1.94 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Relmada Therapeutics have?
Each share of Relmada Therapeutics has $0.11 of cash and investments, as of June 30, 2026.
Has Relmada Therapeutics bought back shares?
Relmada Therapeutics’s share count rose about 36346% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.